Endogenous/Drug effects on receptor COPY bottom half/beta blockers Flashcards
Baroceptor response often stay intact if using
clonidine or dexmedetomidine
Fenoldopam is
what receptor
D1 receptor agonist
vasodilator for acute treatment of severe HTN
Amphetamine and dextroamphetamine
Acts indirectly by releasing biogenic amines
from storage sites in nerve terminals
– Activates RAS
– Can cause psychosis (5-HT mediated)
– Anorectic, locomotor stimulant (DA mediated
Phenoxybenzamine 6 things what is it? where does it bind? causes? enhanced by what? Useful in two things?
-Phenoxybenzamine-vasodilator
-Blocks A1 & A2 irreversibly/Antagonists
-Causes decrease in SVR and increase in CO
(reflex)
– Hypotension enhanced with b2 agonists
– Useful in pheochromocytoma and in
-autonomic hyperreflexia, SC injury
Phentolamine 5 what is it use duration S/E contra in who
Phentolamine Blocks A1 &A2 receptors COMPETITIVELY – Mainly used in preoperative management of pheochromocytoma • Same as phenoxybenzamine, but short-lived (~15 min following IV bolus) – Causes release of histamine • Contraindicated in CAD
Prazosin
Prazosin/CHF
Potent A1 receptor antagonist/no A2 blockade (no increase in NE release)
• Blocks A1 receptors in arterioles
• Decreases SVR & venous return to heart
– Does not usually cause increase in HR or SV
• half-life 2-3 hours
• Terazosin (Hytrin®) is structural analog of
prazosin
– Also has high specificity for A1 receptors
A1-Adrenergic Antagonists
Therapeutic uses
2
A1-Adrenergic Antagonists
Therapeutic uses
-CHF/A1 receptor blockade dilates arteries
• Decrease afterload and preload
-BPH
• A1 receptor antagonists reduce resistance in some
patients
• A1 receptors in bladder trigone and urethra contribute to
blockage
• Essential hypertension & prostatic hypertrophy
(prazosin, doxazosin, terazosin)
Yohimbine
inhibits what
Erectile dysfunction (Yohimbine) • Blockade with selective antagonists (yohimbine) can increase sympathetic outflow A2 receptor antagonist • Increase SNS activity • Inhibits the function of monoamine oxidase enzymes
Therapeutic Uses of A Blockers
(Antagonists)
5
- Hypertension
- Pheochromocytoma
- Benign prostatic hyperplasia
- Peripheral vascular disease
- Erectile dysfunction (Yohimbine)
Beta Antagonists (B-Blockers) used to treat 4
Used to Tx: CAD, HTN, HF, tachydysrhythmias
Cardiac selective (β1 receptor) drugs
Atenolol, metoprolol, esmolol
-Relative selectivity; much less vascular, bronchial smooth
muscle, and metabolic effects
Beta blockers Intrinsic sympathomimetic activity (ISA) (partial
agonist activity) drugs
Pindolol, acebutolol
Less slowing of HR at rest; exercise induced ↑ HR still blunted
like non-ISA β-blockers
Beta blocker Membrane stabilizing activity (MSA)
Acebutolol, labetalol, metoprolol, pindolol, and
propranolol
Beta blocker that vasodilates
Nebivolol vasodilates via endothelial dependent
NO pathway
B antagonists block
renin release caused by
SNS stimulation
Reduction in plasma renin activity causes anti-HTN
Beta blockers cause these negative effects on the heart
decreased sinus rate, spontaneous &
depolarization of ectopic foci
Propranolol is life threating to what patient population? Why
COPD & asthma
blocks B2 receptor
Beta blockers cause hypoglycemia. Why ?
4
Beta blockers cause hypoglycemia. Why ?
Metabolic effects
– Catecholamines promote glycogenolysis and mobilize glucose in response to hypoglycemia
-B adrenergic antagonists may block this response
-B2 receptor blockade may inhibit hepatic
response to insulin-induced hypoglycemia
-B3 adrenergic antagonists attenuate the
release of free fatty acids from adipose tissue
Propranolol
non selective beta
Interacts with B1& B2 receptors with equal
affinity
Highly lipophilic with large VD
• Crosses BBB
– Lacks intrinsic sympathomimetic activity
– Extensively metabolized
– Propranolol may be administered IV for
management of life-threatening dysrhythmias
or to patients under anesthesia
• 1-3 mg administered slowly
• If bradycardia is profound - atropine may be used
Metoprolol
Metoprolol – β1/β2-receptor affinity (30:1); membrane stabilizing activity (MSA); no ISA – Primarily liver metabolism – ½ as potent as propranolol – Short elimination half-life 3.5 hrs
Atenolol
β1/β2-receptor affinity (30:1); no MSA or ISA
activity
– Primarily excreted via kidneys; no first-pass
metabolism
– Elimination half-life 6.5 hrs, so once daily dosing